Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's oesophagus that offers promise for preventing deaths from oesophageal adenocarcinoma.

Barrett's oesophagus (BE) is the precursor lesion of oesophageal adenocarcinoma (EAC), a highly lethal cancer with more than 80 percent mortality at five years.

Lethal EAC can be prevented when patients are diagnosed at the precursor stage of Barrett's oesophagus, and early foci of near cancerous changes (dysplasias) are ablated.

However, detection of BE has traditionally necessitated endoscopy, an expensive and invasive test that requires sedation and is thus unsuitable as a method for wide BE screening.

In a significant step forward, the team has developed an easy, five minute outpatient test that is more than 90 percent sensitive for detecting individuals with BE.

Patients simply swallow a vitamin pill sized balloon that swabs the oesophagus, and that, after retrieval through the mouth, is tested for DNA abnormalities that the investigators discovered are diagnostic of BE.

A study describing the development of the test and the results from its clinical trial in patients has been published in Science Translational Medicine.

The swallowable balloon device was developed by Case Western Reserve School of Medicine faculty and University Hospitals physicians Amitabh Chak, MD (Professor of Medicine and head of the NIH-Case Barrett's Oesophagus Translational Research Network "BETRNet" program), Joseph Willis, MD (Professor of Pathology and Pathology Vice-Chair for Clinical Affairs), and Sanford Markowitz, MD, PhD (Ingalls Professor of Cancer Genetics and head of the NIH-Case GI Cancers "SPORE" Program of Research Excellence).

Helen Moinova, PhD, study first author and instructor at Case Western Reserve School of Medicine, led a parallel effort within the Markowitz laboratory to identify DNA changes diagnostic of Barrett's.

Using genome-wide sequencing approaches, Dr. Moinova identified two genes, VIM and CCNA1, that each get chemically modified by DNA methylation in BE.

Dr. Moinova's DNA methylation test was more than 90 percent accurate in detecting BE or in recognising an oesophagus as normal in a set of more than 300 oesophagus endoscopy samples collected by Dr. Chak's multicenter BETRNet team.

Under sponsorship from the SPORE and BETRNet programs, Dr. Chak then led a clinical trial in which 86 individuals were tested using the swallowable oesophageal balloon device.

Dr. Moinova's DNA assay of these balloon samples was again more than 90 percent accurate, with 90.3 percent sensitivity for detecting individuals with BE and 91.7 percent specificity for correctly identifying individuals who were normal.

"Our goal is early detection," said Dr. Chak. "Symptoms of Barrett's oesophagus, such as heartburn, can also be commonly seen in individuals who have acid reflux disease without BE. These symptoms can easily be treated by over the counter medications so people often don't get tested for BE, particularly by an invasive test such as endoscopy. As a result, when individuals develop EAC, 95 percent of the time the presence of the prior Barrett's oesophagus was undetected and unknown. We wanted an easier, less costly test that could provide a practical way for screening and early detection of individuals with BE, who can then be followed closely to prevent development of EAC."

In the clinical trial, patients tolerated the balloon test well, with 82 percent reporting little to no anxiety, pain, or choking, 93 percent stating they would repeat the procedure again, and 95 percent stating they would recommend the test to others.

The balloon device that patients swallowed is a pill-sized capsule attached to a thin silicone catheter. After delivery to the stomach, the small balloon was inflated by injecting air through the catheter.

The inflated balloon was maneuvered to swab the lower esophagus near the stomach, the region where BE begins, and obtain a sample of the lining cells.

Surface texturing on the balloon increased the effectiveness of the sampling.

The balloon was then deflated through the catheter and inverted back into the capsule, thus protecting the oesophagus sample from dilution or contamination.

After retrieval of the capsule through the mouth, DNA was extracted from the balloon surface for the DNA methylation test.

In an earlier study, the team had previously identified that VIM DNA methylation is common in BE.

The genomic technology employed in the new study discovered CCNA1 DNA methylation is equally common in BE.

"Having two accurate biomarkers increases confidence in our ability to correctly diagnose Barrett's oesophagus," said Dr. Moinova. "Taken together, our findings show that non-endoscopic balloon sampling paired with molecular tests for the methylated VIM and CCNA1 biomarkers is effective in addressing the need for simple, non-invasive, safe, and accurate Barrett's oesophagus screening."

Dr. Willis is currently leading an NIH supported effort to implement the VIM and CCNA1 DNA tests as a standardised clinical test that will be provided by the University Hospital's pathology department.

Dr. Markowitz noted that, "We are fortunate to be the only academic medical center in the country to which the NIH has awarded both a GI Cancers SPORE and a BETRNet program. The $18 million in support from these NIH awards has allowed us to build a premier team for developing new approaches for early detection, prevention and treatment of GI cancers. However, credit for this advance most importantly belongs to each of the patients who so generously participated in the clinical trial of this exciting new technology."

Source: Case Western Reserve University